An update on the management of nephropathy in type 2 diabetes

Hai Lu Zhao, G. Neil Thomas, Wilson Leung, Brian Tomlinson, Yung Ho Hsu, Paul Chan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background. To provide an update on the latest evidence-based management of nephropathy in type 2 diabetes. Methods. A literature search (MEDLINE 1966 to 2002) was performed using the key words "diabetic nephropathy," and relevant book chapters were also reviewed, to identify well-controlled, prospective landmark studies and expert review articles on diabetic nephropathy (DN). Data and conclusions from the selected articles that Provided solid evidence regarding the optimal management of DN were extracted and interpreted in light of clinical and research experience with Chinese patients. Results. DN is the leading cause of end-stage renal disease worldwide. High blood pressure, dyslipidemia, long duration of diabetes, poor glycemic control and central obesity are important risk factors. Microalbuminuria is a practical marker to predict the development of overt nephropathy in type 2 diabetic patients. Risk factor modification, renal function monitoring and combined therapies are the current integrated approaches to manage patients with diabetic kidney disease. Optimal glycemic control is a fundamental goal, but effective antihypertensive and possibly lipid-lowering therapy delay the progression of DN. Recent large clinical trials support the earlier experimental data that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have important renoprotective actions independent of their blood pressure lowering actions. Conclusions. Screening for microalbuminuria and monitoring renal function will identify patients with DN at an early stage and allow for intervention. Tight glycemic control and aggressive antihypertensive treatment as well as the use of renin-angiotensin system inhibitors should substantially delay the progression of nephropathy.

Original languageEnglish
Pages (from-to)627-636
Number of pages10
JournalJournal of the Chinese Medical Association
Volume66
Issue number11
Publication statusPublished - Nov 2003

Fingerprint

Diabetic Nephropathies
Type 2 Diabetes Mellitus
Antihypertensive Agents
Kidney
Abdominal Obesity
Angiotensin Receptor Antagonists
Renin-Angiotensin System
Dyslipidemias
Angiotensin-Converting Enzyme Inhibitors
MEDLINE
Chronic Kidney Failure
Therapeutics
Clinical Trials
Prospective Studies
Blood Pressure
Hypertension
Lipids
Research

Keywords

  • Albuminuria
  • Hypertension
  • Nephropathy
  • Renin-angiotensin system
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

An update on the management of nephropathy in type 2 diabetes. / Zhao, Hai Lu; Thomas, G. Neil; Leung, Wilson; Tomlinson, Brian; Hsu, Yung Ho; Chan, Paul.

In: Journal of the Chinese Medical Association, Vol. 66, No. 11, 11.2003, p. 627-636.

Research output: Contribution to journalArticle

Zhao, HL, Thomas, GN, Leung, W, Tomlinson, B, Hsu, YH & Chan, P 2003, 'An update on the management of nephropathy in type 2 diabetes', Journal of the Chinese Medical Association, vol. 66, no. 11, pp. 627-636.
Zhao, Hai Lu ; Thomas, G. Neil ; Leung, Wilson ; Tomlinson, Brian ; Hsu, Yung Ho ; Chan, Paul. / An update on the management of nephropathy in type 2 diabetes. In: Journal of the Chinese Medical Association. 2003 ; Vol. 66, No. 11. pp. 627-636.
@article{3fa6ba830151435d81a62429d20bb8f7,
title = "An update on the management of nephropathy in type 2 diabetes",
abstract = "Background. To provide an update on the latest evidence-based management of nephropathy in type 2 diabetes. Methods. A literature search (MEDLINE 1966 to 2002) was performed using the key words {"}diabetic nephropathy,{"} and relevant book chapters were also reviewed, to identify well-controlled, prospective landmark studies and expert review articles on diabetic nephropathy (DN). Data and conclusions from the selected articles that Provided solid evidence regarding the optimal management of DN were extracted and interpreted in light of clinical and research experience with Chinese patients. Results. DN is the leading cause of end-stage renal disease worldwide. High blood pressure, dyslipidemia, long duration of diabetes, poor glycemic control and central obesity are important risk factors. Microalbuminuria is a practical marker to predict the development of overt nephropathy in type 2 diabetic patients. Risk factor modification, renal function monitoring and combined therapies are the current integrated approaches to manage patients with diabetic kidney disease. Optimal glycemic control is a fundamental goal, but effective antihypertensive and possibly lipid-lowering therapy delay the progression of DN. Recent large clinical trials support the earlier experimental data that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have important renoprotective actions independent of their blood pressure lowering actions. Conclusions. Screening for microalbuminuria and monitoring renal function will identify patients with DN at an early stage and allow for intervention. Tight glycemic control and aggressive antihypertensive treatment as well as the use of renin-angiotensin system inhibitors should substantially delay the progression of nephropathy.",
keywords = "Albuminuria, Hypertension, Nephropathy, Renin-angiotensin system, Type 2 diabetes",
author = "Zhao, {Hai Lu} and Thomas, {G. Neil} and Wilson Leung and Brian Tomlinson and Hsu, {Yung Ho} and Paul Chan",
year = "2003",
month = "11",
language = "English",
volume = "66",
pages = "627--636",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "11",

}

TY - JOUR

T1 - An update on the management of nephropathy in type 2 diabetes

AU - Zhao, Hai Lu

AU - Thomas, G. Neil

AU - Leung, Wilson

AU - Tomlinson, Brian

AU - Hsu, Yung Ho

AU - Chan, Paul

PY - 2003/11

Y1 - 2003/11

N2 - Background. To provide an update on the latest evidence-based management of nephropathy in type 2 diabetes. Methods. A literature search (MEDLINE 1966 to 2002) was performed using the key words "diabetic nephropathy," and relevant book chapters were also reviewed, to identify well-controlled, prospective landmark studies and expert review articles on diabetic nephropathy (DN). Data and conclusions from the selected articles that Provided solid evidence regarding the optimal management of DN were extracted and interpreted in light of clinical and research experience with Chinese patients. Results. DN is the leading cause of end-stage renal disease worldwide. High blood pressure, dyslipidemia, long duration of diabetes, poor glycemic control and central obesity are important risk factors. Microalbuminuria is a practical marker to predict the development of overt nephropathy in type 2 diabetic patients. Risk factor modification, renal function monitoring and combined therapies are the current integrated approaches to manage patients with diabetic kidney disease. Optimal glycemic control is a fundamental goal, but effective antihypertensive and possibly lipid-lowering therapy delay the progression of DN. Recent large clinical trials support the earlier experimental data that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have important renoprotective actions independent of their blood pressure lowering actions. Conclusions. Screening for microalbuminuria and monitoring renal function will identify patients with DN at an early stage and allow for intervention. Tight glycemic control and aggressive antihypertensive treatment as well as the use of renin-angiotensin system inhibitors should substantially delay the progression of nephropathy.

AB - Background. To provide an update on the latest evidence-based management of nephropathy in type 2 diabetes. Methods. A literature search (MEDLINE 1966 to 2002) was performed using the key words "diabetic nephropathy," and relevant book chapters were also reviewed, to identify well-controlled, prospective landmark studies and expert review articles on diabetic nephropathy (DN). Data and conclusions from the selected articles that Provided solid evidence regarding the optimal management of DN were extracted and interpreted in light of clinical and research experience with Chinese patients. Results. DN is the leading cause of end-stage renal disease worldwide. High blood pressure, dyslipidemia, long duration of diabetes, poor glycemic control and central obesity are important risk factors. Microalbuminuria is a practical marker to predict the development of overt nephropathy in type 2 diabetic patients. Risk factor modification, renal function monitoring and combined therapies are the current integrated approaches to manage patients with diabetic kidney disease. Optimal glycemic control is a fundamental goal, but effective antihypertensive and possibly lipid-lowering therapy delay the progression of DN. Recent large clinical trials support the earlier experimental data that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have important renoprotective actions independent of their blood pressure lowering actions. Conclusions. Screening for microalbuminuria and monitoring renal function will identify patients with DN at an early stage and allow for intervention. Tight glycemic control and aggressive antihypertensive treatment as well as the use of renin-angiotensin system inhibitors should substantially delay the progression of nephropathy.

KW - Albuminuria

KW - Hypertension

KW - Nephropathy

KW - Renin-angiotensin system

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0347765864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347765864&partnerID=8YFLogxK

M3 - Article

C2 - 14768849

AN - SCOPUS:0347765864

VL - 66

SP - 627

EP - 636

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 11

ER -